AVTR stock forecast, quote, news & analysis
Avantor Inc provides products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries... Show more
Avantor (AVTR) Stock Analysis: Revival Strategy Returns the Company to Organic Growth
Key Takeaways
- Avantor (AVTR) traded near $16.27 in late October 2026, up roughly 6% from its level 30 days earlier, reflecting a steady uptrend rather than a sharp, volatile spike.
- Third-quarter 2026 results marked a return to organic revenue growth of 5.2%, with net sales of $1.70 billion rising 4.6% year over year and exceeding consensus estimates.
- Both operating segments expanded: VWR Distribution & Services grew 5.8% organically, while Bioscience & Medtech Products returned to growth at 3.6%.
- Management raised full-year 2026 guidance for organic revenue growth, adjusted earnings per share, and free cash flow, citing improving execution and stronger end markets.
- The company's "Revival" program — focused on commercial execution, digital capabilities, and cost discipline — sits at the center of the improving operating trend.
- Analyst sentiment remains mixed, with a consensus Hold rating and average price targets generally below the prevailing share price.
- For deeper context on valuation and forward estimates, explore Avantor's Price Targets, Earnings, and Forecast pages.
- Investors seeking systematic, data-driven trading ideas can also explore Tickeron's Trending AI Robots.
Current Market Snapshot
Avantor shares have advanced in a measured fashion over the trailing month, gaining roughly 6% while the broader market has moved more modestly. The stock has outperformed the S&P 500 on a year-to-date basis, with the rally supported by a return to revenue growth and successive quarterly earnings beats. Market capitalization stands near $11.6 billion, and the shares have attracted notable institutional turnover, with several large asset managers adding positions during the year's second quarter.
Despite the upward trajectory, sell-side analysts remain broadly neutral. The consensus rating is Hold, and the average 12-month price target sits below the current price, indicating that much of the near-term optimism tied to the company's turnaround may already be reflected in the share price.
Avantor (AVTR) Business Overview and Competitive Position
Avantor, Inc., headquartered in Radnor, Pennsylvania, is a global provider of mission-critical products and services to customers in the life sciences and advanced technology industries. The company serves more than 300,000 customer locations across 180 countries, supplying laboratory consumables, chemicals, equipment, and services that support research, development, and production workflows.
The business operates through two primary segments. The VWR Distribution & Services segment delivers lab supplies, equipment, and services to biopharmaceutical, healthcare, education, and government customers. The Bioscience & Medtech Products segment provides proprietary materials, including process chemicals and high-performance silicone products, used in bioprocessing and medical device manufacturing.
Avantor's scale, broad product portfolio, and embedded position within customer supply chains are key competitive strengths. The company is also a meaningful barometer for global research-and-development spending, making it closely watched by investors seeking exposure to the life sciences tools and consumables cycle.
Recent Developments Driving AVTR
The dominant catalyst over the past month was Avantor's third-quarter 2026 earnings report. The company posted net sales of $1.698 billion, up 4.6% on a reported basis and 5.2% organically, surpassing consensus revenue estimates of roughly $1.64 billion. Adjusted earnings per share of $0.22 also came in ahead of expectations. GAAP net income reached $203.4 million, a sharp improvement from a net loss of $711.8 million in the prior-year quarter, which had been weighed down by a $785 million impairment charge.
Management highlighted accelerating momentum in the VWR segment and a return to organic growth in Bioscience & Medtech Products. In response, the company raised its full-year 2026 guidance for organic revenue growth to a range of 0.75% to 1.25%, for adjusted EPS to $0.81 to $0.83, and for free cash flow to $525 million to $550 million.
Leadership changes also featured in the period, including the appointment of a new chief financial officer in September and a new chief information officer in late October, completing the executive team executing the Revival program. On the analyst front, several firms raised their price targets during the month, though the overall consensus rating remained Hold.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-driven trading bots from a broader platform that offers hundreds of automated strategies across thousands of tickers. Only the top-performing and most relevant bots are featured in this section, giving users a focused view of strategies that are currently resonating with market conditions. The bots vary widely in approach, holding timeframe, and performance metrics, allowing traders to compare options aligned with different objectives and risk tolerances. The page is designed to help users discover systematic, data-driven trading ideas rather than rely on emotion or manual discretion. Exploring the section can serve as a useful starting point for investors interested in supplementing their own research with quantitative signals.
2026 Outlook and What Investors Should Watch
Looking ahead, the central theme for Avantor is whether the return to organic growth can be sustained and broadened. Investors should monitor whether the VWR segment continues to benefit from improved commercial execution and whether Bioscience & Medtech Products maintains its positive trajectory as supply-chain and throughput initiatives mature.
End-market conditions will remain critical. Management has pointed to strengthening demand from large pharmaceutical and biotechnology customers, early signs of recovery in higher education and early-stage biotech, and solid activity in certain industrial subsectors. Europe, however, continues to lag, and any improvement there would represent an incremental tailwind.
Balance-sheet progress is another focal point, with management targeting an adjusted net leverage ratio below 3x by year-end. Macroeconomic risks, including foreign-exchange movements, inflationary cost pressures, and funding headwinds for government-supported research, could still influence results. Analysts' cautious stance — reflected in a Hold consensus and price targets below the market price — suggests that further share-price appreciation will likely depend on continued execution and evidence of durable, broad-based growth.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for AVTR turns positive, indicating new upward trend
AVTR saw its Momentum Indicator move above the 0 level on October 05, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 89 similar instances where the indicator turned positive. In 61 of the 89 cases, the stock moved higher in the following days. The odds of a move higher are at 69%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for AVTR just turned positive on October 15, 2026. Looking at past instances where AVTR's MACD turned positive, the stock continued to rise in 28 of 45 cases over the following month. The odds of a continued upward trend are 62%.
Following a +5.96% 3-day Advance, the price is estimated to grow further. Considering data from situations where AVTR advanced for three days, in 172 of 273 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.
The Aroon Indicator entered an Uptrend today. In 112 of 174 cases where AVTR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 64%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AVTR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 73%.
AVTR broke above its upper Bollinger Band on October 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 23 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.058) is normal, around the industry mean (4.942). P/E Ratio (-20.153) is within average values for comparable stocks, (37.224). Projected Growth (PEG Ratio) (0.840) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (1.614) is also within normal values, averaging (56.876).
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. AVTR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 93 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 99 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AVTR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of laboratory chemicals
Industry PharmaceuticalsOther